Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1702
- Development stage
- Phase 1
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-1702 is a humanized monoclonal antibody that targets T-cell immunoglobulin and mucin-domain containing-3 (TIM-3, also known as HAVCR2). By binding to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes, SHR-1702 blocks the inhibitory signaling mediated by TIM-3. This blockade is intended to enhance anti-tumor immune responses by promoting T-cell activation and proliferation. The drug has been investigated for its potential in treating hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as solid tumors. Its mechanisms include antibody-dependent cell cytotoxicity, inhibition of HAVCR2 protein (TIM-3), and stimulation of T lymphocytes[2][3][4].
- Other names
- SHR 1702SHR1702SHR-1702
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on SHR-1702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1702.